Seikagaku
4548.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥36.6bn | ¥39.4bn | ¥36.2bn | ¥33.5bn | ¥34.9bn | ¥27.7bn |
| Operating income | −¥660m | ¥1.3bn | ¥433m | ¥2.1bn | ¥4.5bn | ¥2.2bn |
| Ordinary income | ¥1.7bn | ¥1.9bn | ¥1.7bn | ¥3.1bn | ¥5.4bn | ¥3.0bn |
| Net income (owners) | ¥1.5bn | ¥1.2bn | ¥2.2bn | ¥2.2bn | ¥3.7bn | ¥4.3bn |
| Total assets | ¥86.3bn | ¥83.9bn | ¥81.8bn | ¥75.6bn | ¥75.2bn | ¥69.9bn |
| Net assets / equity | ¥75.3bn | ¥73.2bn | ¥72.3bn | ¥67.2bn | ¥66.3bn | ¥63.6bn |
| Operating cash flow | −¥1.3bn | ¥4.4bn | ¥513m | ¥1.6bn | ¥8.2bn | ¥1.3bn |
| EPS (basic) | ¥26.99 | ¥22.25 | ¥40.08 | ¥40.49 | ¥66.32 | ¥75.54 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2025-09-30 | Half-year | 71 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 71 figures · EDINET |
22 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| LAL | ¥12.2bn | ¥975m |
| Pharmaceutical | ¥24.5bn | −¥1.6bn |
| Total | ¥36.6bn | −¥660m |
Segment names from EDINET member IDs; not mapped to a common taxonomy.